Chonluten

What it is

Chonluten is a three-amino-acid Khavinson bioregulator aimed at the lining of the airways. People with a lingering cough, an ex-smoker's chest, or breathing that never fully bounced back after an infection run it in short courses hoping for clearer, calmer airways. The evidence is cell work from one institute; the injectable has no human trial at all.

The people who try it are ex-smokers with a morning cough, people with mild asthma or bronchitis who flare every winter, and the long-COVID crowd whose chest never felt normal again. It is a bioregulator, which means a tiny fragment peptide proposed to nudge gene expression in one tissue, here the bronchi and lungs, rather than a drug with a receptor and a dose-response curve. It is not a rescue inhaler, not an antibiotic, and it will not touch real COPD or an infection.

If it does anything, it is subtle and slow: people who report a benefit describe less morning mucus and an easier chest two to four weeks after a course, which is after the course has ended. Most notice nothing. There is no acute effect, so there is nothing to titrate to. If a 20-day course changes nothing by six weeks out, it is not going to.

Our doses are 100 mcg to start, 200 mcg standard and 500 mcg at most, once a day subQ, for 10 to 20 days (up to 30), then a few months off before the next course, two or three courses a year, close to how the Russian capsules are scheduled. The gap is not about tolerance: the effect is meant to carry on for months after a course, so running it straight through gains nothing. A 20 mg vial in 3 ml is about 6.7 mg/ml, so 200 mcg is 3 units on an insulin syringe. The cost reality is waste: a 20-day course at 200 mcg uses 4 mg, a fifth of the vial, and the mix only keeps about four weeks, so most of what you bought goes in the bin. The mistake is following vendor protocols that ramp to several milligrams a day over 16 weeks; nothing in the research supports that, and it is a way to spend a lot on an unproven peptide.

The evidence is thin even by bioregulator standards. The work is cell cultures of airway and immune cells from the St Petersburg institute that developed the whole class, showing changes in genes tied to mucus production and ciliary clearance. The oral capsule is sold in Russia as a supplement, not a licensed medicine, and the injectable microgram protocol is a Western community convention with no human data behind it. It is not approved anywhere.

If your chest problem is immune, with frequent infections, Thymosin Alpha-1 has real human evidence and approvals abroad. If it is inflammatory, VIP is the better-studied peptide for airways. If it is asthma or COPD, your inhalers do more than any peptide here. Chonluten is the cheap, low-risk thing to try after those, in one course, with a clear note of what you were hoping to change.

What people use it for

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LineAvolio et al., Int J Mol Sci 2022 · Study